Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2024-02-15 Earnings Release
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives
Earnings Release Classification · 100% confidence The document explicitly announces the 'results for the fourth quarter and for the full year 2023' for Navamedic ASA. It contains key financial metrics (Revenues, Gross Margin, EBITDA, EBIT) for both the quarter and the full year, along with management commentary and outlook. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often summarized before the full quarterly report (IR) or annual report (10-K) is filed. Since it focuses on the immediate release of period results, ER is the most appropriate classification. It is not a full transcript (CT), a formal annual report (10-K), or an interim report (IR) which is typically more comprehensive than this summary announcement. Q4 2023
2024-02-15 English
Navamedic ASA: Invitation to 2023 4th quarter presentation
Report Publication Announcement Classification · 98% confidence The document is titled "Navamedic ASA: Invitation to 2023 4th quarter presentation" and explicitly states that the company "will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024." It provides details about the time, location, and a link to the webcast/presentation. This is not the actual earnings release (ER) or the comprehensive interim report (IR), but rather an announcement about the upcoming presentation of those results. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement regarding the publication or presentation of results falls under Report Publication Announcement (RPA).
2024-02-13 English
Navamedic ASA launches Eroxon®
Regulatory Filings Classification · 100% confidence The document is a short press release from Navamedic ASA announcing the acquisition of rights to market and distribute Eroxon® in the Nordic countries and its subsequent launch in Norway. It details product information, market strategy, and contact details. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a general announcement regarding business operations and product distribution, and it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), the most appropriate general category for a significant, non-standard business update that is not a formal financial report is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements.
2024-02-12 English
Navamedic ASA: Renewed contract signed with Vitaflo International Limited
Regulatory Filings Classification · 100% confidence The document is a short press release from Navamedic ASA announcing the renewal of a distribution contract with Vitaflo International Limited for an additional five years. This type of announcement, detailing a significant business agreement or operational update that doesn't fit into standard financial reporting categories (like 10-K, ER, or IR), is best classified as a general regulatory announcement or news release. Since it is not a formal financial report, a management change, a dividend notice, or a specific legal filing, the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers miscellaneous regulatory announcements.
2023-12-21 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. It is not the report itself, but rather an announcement detailing *when* reports and meetings will occur. Since it is an announcement about the publication schedule of various reports, it fits best under Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2023-12-15 English
Navamedic ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing a transaction involving a person discharging managerial responsibilities ('Åsa Kornfeld', a 'Board member') in the issuer ('Navamedic ASA'). Specifically, it reports a 'Share purchase' of 1,300 shares on 2023-12-14. This structure and content directly correspond to the definition of Director's Dealing (insider trades by executives/directors).
2023-12-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.